Company: PRTA
Filing Date: 2025-06-18
Form Type: 8-K
Source: 0001193125-25-142725
Chunk: 1

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-06-18
Form: 8-K
Item: Item 5.02
Chunk 1
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025. Such termination will trigger certain payments and benefits to Ms. Karp and Mr. Ford under the terms of the Prothena Biosciences Inc Amended and Restated Severance Plan and acceleration of a portion of their stock options and the post-employment exercise periods will be extended pursuant to the terms of their option award agreements under which those stock options were granted, all as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on March 28, 2025.